menu
    • menu

    Company profile for Veloxis Pharmaceuticals

    NEW Drugs in Dev: 6
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis has successfully developed ENVARSUS XR (tacrolimus extended-release tablets...
    Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis has successfully developed ENVARSUS XR (tacrolimus extended-release tablets) based upon the company’s unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Veloxis PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1001 Winstead Drive, Cary, NC 27513
    Telephone
    Telephone
    1 919 591 3090
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.panpharma.eu/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/panpharma/?originalSubdomain=fr
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    IMCAS World Congress

    IMCAS World Congress

    Not Confirmed

    envelop Contact Supplier

    IMCAS World Congress

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    OSE Immunotherapeutics Welcomes FDA Orphan Designation
    OSE Immunotherapeutics Welcomes FDA Orphan Designation

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3223109/0/en/OSE-Immunotherapeutics-Welcomes-FDA-Orphan-Drug-Designation-Granted-to-Pegrizeprument-VEL-101.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    Pegrizeprument Receives Orphan Drug Status For Liver Transplant
    Pegrizeprument Receives Orphan Drug Status For Liver Transplant

    21 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pegrizeprument-granted-orphan-drug-designation-for-prevention-of-organ-rejection-in-patients-receiving-a-liver-transplant-302666801.html

    PR NEWSWIRE
    21 Jan 2026
    Share Share
    Veloxis Pharmaceuticals Presenting at 2025 Transplant Congress
    Veloxis Pharmaceuticals Presenting at 2025 Transplant Congress

    30 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-to-present-at-2025-world-transplant-congress-302516650.html

    PR NEWSWIRE
    30 Jul 2025
    Share Share
    Veloxis Pharma's VEL-101 Gets USAN Approval As Pegrizeprument
    Veloxis Pharma's VEL-101 Gets USAN Approval As Pegrizeprument

    25 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-receives-approval-from-usan-for-pegrizeprument-as-nonproprietary-name-for-vel-101-302384616.html

    PR NEWSWIRE
    25 Feb 2025
    Share Share
    Veloxis Selected For Presentation At ATC 2024 In Philadelphia
    Veloxis Selected For Presentation At ATC 2024 In Philadelphia

    30 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-selected-to-present-at-the-2024-american-transplant-congress-in-philadelphia-302158666.html

    PR NEWSWIRE
    30 May 2024
    Share Share
    Lyfebulb & Veloxis Announce Finalists for Challenge in Organ Transplantation
    Lyfebulb & Veloxis Announce Finalists for Challenge in Organ Transplantation

    19 Sep 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/lyfebulb-and-veloxis-pharmaceuticals-announce-finalists-for-2022-innovation-challenge-in-organ-transplantation-301627424.html

    PRNEWSWIRE
    19 Sep 2022
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search